Literature DB >> 12940874

Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance.

B I Shand1, R S Scott, P A Elder, P M George.   

Abstract

AIM: Adiponectin is a protein produced exclusively by adipocytes with putative insulin-sensitizing and anti-atherogenic properties. This cross-sectional study investigated the relationship between plasma adiponectin and a range of anthropometric, glycaemic, lipid and inflammatory parameters in overweight and obese subjects expressing characteristics of the metabolic syndrome.
METHODS: Subjects were selected for the study from a clinical database, if they were non-diabetic, overweight [body mass index (BMI) > 25] and had features of the metabolic syndrome. The subjects were grouped according to BMI (25-30, 31-35 and >35 kg/m2) and then stratified for insulin resistance [homeostasis model assessment (HOMA) %S]. One hundred and ninety-seven patients (109 males and 88 females) were selected for the study by taking an equal number with the highest and lowest HOMA indices from each of the three BMI groups. Plasma adiponectin concentration was measured in duplicate by radioimmunoassay, and the relationship between these levels and the other parameters was investigated using correlation and multiple linear regression analyses.
RESULTS: Plasma adiponectin concentration was higher in females than males (median 10.3 vs. 7.1 micro g/ml, p < 0.001) despite being matched for BMI. In both genders, adiponectin levels were inversely related to BMI, waist circumference, percentage body fat, insulin resistance and the fasting plasma concentration of leptin. A direct correlation in both sexes was found between adiponectin levels and high-density lipoprotein (HDL)-cholesterol, apolipoprotein A1 and age. Multiple linear regression analyses showed that the independent determinants of low plasma adiponectin concentrations were gender, age, BMI, insulin resistance and HDL-cholesterol. An association between reduced adiponectin and increased high-sensitivity plasma C-reactive protein concentration was observed only in female subjects and was independent of anthropometric variables. Our observation that adiponectin levels increase with age differs from the majority of other studies and may simply reflect the demographics of the population studied.
CONCLUSIONS: This study shows that adiponectin is an important molecular link between obesity, insulin resistance and atherogenic lipoproteins. It is possible that plasma adiponectin concentration may be a convenient marker for identifying subjects with the metabolic syndrome who may progress to impaired glucose tolerance. Longitudinal studies are required in order to verify this clinical application of adiponectin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940874     DOI: 10.1046/j.1463-1326.2003.00279.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  19 in total

Review 1.  Pharmacogenetics of posttransplant diabetes mellitus.

Authors:  P Lancia; T Adam de Beaumais; E Jacqz-Aigrain
Journal:  Pharmacogenomics J       Date:  2017-03-28       Impact factor: 3.550

2.  Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus.

Authors:  Fatemeh Namvaran; Parvaneh Rahimi-Moghaddam; Negar Azarpira; Mohammad Hosein Dabbaghmanesh
Journal:  Mol Biol Rep       Date:  2011-12-21       Impact factor: 2.316

3.  Adiponectin moderates the relationship between adiposity and leptin in adolescents regardless of gender or race.

Authors:  Vanessa Bundy; Maribeth Johnson; Bernard Gutin; Haidong Zhu; Inger Stallmann-Jorgensen; Yanbin Dong
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

4.  Adiponectin expression and metabolic markers in obesity and Type 2 diabetes.

Authors:  S Kouidhi; S Jarboui; R Marrakchi; M-S Clerget Froidevaux; I Seugnet; H Abid; F Bchir; M Brahem; B Demeneix; H Guissouma; A Benammar Elgaaied
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

5.  Clinically silent adrenal adenomas - their relation to the metabolic syndrome and to GNB3 C825T gene polymorphism.

Authors:  Ivica Lazúrová; Daniela Spišáková; Hedviga Wagnerová; Viera Habalová; Ingrid Dravecká; Petrášová Darina; Ivica Drahovská; Lýdia Pundová
Journal:  Wien Klin Wochenschr       Date:  2011-10-10       Impact factor: 1.704

6.  Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease.

Authors:  Dokyoung Yoon; Seung Hwan Lee; Hye Soon Park; Ji Hoon Lee; Jin Seo Park; Kyung Hwan Cho; Seon Mee Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

7.  Influence of waist on adiponectin and insulin sensitivity in adolescence.

Authors:  Laura J Rasmussen-Torvik; James S Pankow; David R Jacobs; Julia Steinberger; Antoinette M Moran; Alan R Sinaiko
Journal:  Obesity (Silver Spring)       Date:  2008-10-30       Impact factor: 5.002

8.  Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study.

Authors:  Hannah Gardener; Milita Crisby; Charlotte Sjoberg; Barry Hudson; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco
Journal:  Metab Syndr Relat Disord       Date:  2012-11-05       Impact factor: 1.894

9.  The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents.

Authors:  Laura J Rasmussen-Torvik; James S Pankow; David R Jacobs; Julia Steinberger; Antoinette Moran; Alan R Sinaiko
Journal:  Hum Genet       Date:  2008-11-27       Impact factor: 4.132

10.  Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.

Authors:  J Westerbacka; A Cornér; M Tiikkainen; M Tamminen; S Vehkavaara; A-M Häkkinen; J Fredriksson; H Yki-Järvinen
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.